Dual therapy with dolutegravir works well for both first-line and maintenance treatments. Liz Highleyman, July 29, 2019. Pedro Cahn at IAS 2019. Photo by Liz Highleyman. A combination of two drugs, dolutegravir and lamivudine (the drugs in the Dovato co-formulation), continued to suppress viral load, as well as a […]
Treatment simplification strategies. Read More »
July 28, 2019 at 3:00 am EDT Author: Andrew Gibbs Senior Specialist Scientist: Gender and Health Research Unit, Medical Research Council, South African Medical Research Council A closer look at men in South Africa reveals a very complicated picture. It is obvious that practices and behavior
Men and HIV: How poverty, violence, and inequality play a role Read More »
Liz Highleyman July 29, 2019 Image credit: ViiV Healthcare The new HIV insertion inhibitor, fostemsavir, continues to maintain viral suppression in more than half of people with extensive prior treatment experience and highly resistant virus, according to a report at the 10th Society Conference
Rescue therapy with fostemsavir continues to look good at 96 weeks. Read More »
Gavin Conferences is inviting researchers, academics, students, experts, and business professionals worldwide in the fields of sexually transmitted diseases, HIV/AIDS, vaccines, infectious diseases, immunology, virology, and microbiology to participate in the upcoming International Conference on HIV/AIDS in Venice, Italy.
International Conference on HIV/AIDS Mon, February 10-11, 2020 Read More »
By: Venezuela Migration Project @MigraVenezuela JULY 27, 2019 Health Minister Juan Pablo Uribe announced that Colombia will receive 100,000 HIV early detection kits from the U.S. government, which will be made available in several hospitals throughout the country. U.S. Ambassador to Colombia Kevin Whitaker added that in the
The United States will support Colombia in HIV testing among the migrant population. Read More »
Geneva, July 26, 2019 (PAHO/WHO) - Ahead of World Hepatitis Day (July 28), the World Health Organization (WHO) is calling on countries to take advantage of recent reductions in the costs of diagnosing and treating viral hepatitis by increasing investments to eliminate the disease.
WHO urges countries to invest in eliminating hepatitis Read More »
“Many of us thought there was no hope in hell of surviving,” said Frederick Williams, 55, who tested positive for HIV in 1986. “I had waves of friends who died, and they died quickly.” DENISE RYAN Updated: July 28, 2019 Frederick Williams, longtime AIDS survivor
Dr. Peter Center has had to reinvent itself as the face of HIV has changed. Read More »
Results of the first trial of new immunomodulatory drugs presented in Mexico City: Long-acting antibodies and TLR7 agonist in first safety and dose-finding trials in people with HIV. Gus Cairns, July 26, 2019. Grace Chen, NIAID. (File photo: Gus Cairns) Several studies of new types
The search for a cure. Read More »
IAS 2019 A novel pharmacological mechanism of action, the use of dual therapies that can replace the usual antiretroviral regimens, and changes in administration schedules that allow for spacing out treatments are some of the advances being explored in the approach to HIV/AIDS. Editorial Staff July 26, 2019 Regarding research on dual therapy, two
New treatment regimens could change the approach to HIV Read More »
July 26, 2019 Diana Ernst, RPh The data were presented at the 10th International AIDS Society Conference on HIV Science (NIC 2019). Results from a sub-analysis of the DISCOVER trial showed that Descovy therapy (emtricitabine and tenofovir alafenamide), when used for pre-exposure prophylaxis,
